Innovations in Drug Development - September 9, 2015

Health Topics: General Health and Pediatrics

A. James Clark Distinguished Professorship in Molecular Genetics
Innovations in Drug Development: How Children’s National is Taking a Leadership Role in Faster, Better, and Cheaper Drugs

Presented by:

Eric Hoffman, PhD
Director, Research Center for Genetic Medicine, Children’s National
Professor and Chairman, Department of Integrative Systems Biology, George Washington University
Co-Founder, ReveraGen Biopharma

Give Act

Invest in future cures for some of life's most devastating diseases

$10 a month

One time donation

See other ways to give

Share your birthday with a child. Celebrate your life, and give a chance to someone who desperately wants to have as many as you.

Make it happen

Make an Appointment

You Might Also Be Interested In:

Brain Tumor Institute

We bring together a comprehensive team of pediatric oncology and neurology experts, giving children with brain tumors effective, personalized care.

Muscular Dystrophies

Muscular dystrophy describes a genetic disorder of the muscles that causes the muscles in the body to become very weak.

Rare Diseases Expert Talks about Research in Duchenne Treatments

Eric Hoffman, PhD, discusses the progress in discovering novel treatments for Duchenne muscular dystrophy with the Washington Post.

International Consortium Provides $2M Funding for Phase 1 Clinical Trial of ReveraGen DMD Drug

A novel anti-inflammatory in development for the chronic treatment of Duchenne muscular dystrophy by ReveraGen BioPharma, a private spin-off company from Children’s National Health System, has received $2 million from four nonprofit organizations.